Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung CancerJustin F. Gainor, Ted W. Johnson, Ramin Sakhtemani et al.|Clinical Cancer Research|2021Cited by 137
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung CancersNoura J. Choudhury, Helena A. Yu, Antonio Marra et al.|Journal of Thoracic Oncology|2022Cited by 95